Diabetic Retinopathy

For type 2 diabetes, obtain a dilated fundus examination or validated retinal photographic assessment at diagnosis, then at least annually. For type 1 diabetes, begin annual screening 5 years after disease onset. Retinal photography is an acceptable screening pathway when images are gradable and linked to a defined referral process; an ungradable photograph requires eye examination rather than reassurance. PubMed+2PubMedRecently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilitiesPubMedDiabetic Retinopathy - StatPearls - NCBI BookshelfaaojournalDiabetic Retinopathy Preferred Practice Pattern® - Ophthalmology

Shorten follow-up once nonproliferative diabetic retinopathy (NPDR) is identified. Mild-to-moderate NPDR is generally followed every 6 to 12 months, whereas severe NPDR and non-high-risk proliferative diabetic retinopathy (PDR) warrant examinations every 2 to 4 months because progression to vision-threatening disease is more likely. The likelihood of diabetic macular edema rises with NPDR severity: 15.6% with mild, 44.6% with moderate, and 62.6% with severe NPDR. ccjmccjmPrint Article | Cleveland Clinic Journal of medicine

Expedite retina evaluation for reduced vision, suspected center-involving diabetic macular edema (DME), severe NPDR, any retinal or disc neovascularization, vitreous/preretinal hemorrhage, or suspected tractional retinal detachment. These findings identify sight-threatening diabetic retinopathy and require management beyond routine screening. PubMed+2PubMedNonmydriatic Photographic Screening for Diabetic Retinopathy in Pregnant Patients with Pre-Existing Diabetes in a Safety Net Population: 1 Year Results from the Diabetic Retinopathy in Pregnant Patients Study - PMCPubMedGuidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings - PubMedPubMedDiabetic retinopathy - ocular complications of diabetes mellitus - PMC

Obtain structural macular OCT when visual symptoms, reduced acuity, retinal thickening, or exudates raise concern for DME. OCT determines whether edema involves the center and provides an anatomic baseline for anti-VEGF, corticosteroid, laser, or traction-directed decisions. Fluorescein angiography (FA) remains the reference angiographic test when the question is leakage, retinal nonperfusion, intraretinal microvascular abnormalities, or neovascularization. Wolters Kluwer+1Wolters KluwerEvidence-based review of diabetic macular edema... : Indian Journal of OphthalmologyPubMedOptical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy - PMC

Use FA when clinical examination does not adequately define the leakage pattern, ischemic burden, or suspected proliferative lesion. On FA, microaneurysms appear as punctate hyperfluorescence, while nonperfusion appears as hypofluorescent capillary-deficient areas bordered by larger retinal vessels. Identifying neovascularization supports treatment of PDR to prevent vitreous hemorrhage and tractional retinal detachment. PubMed+1PubMedOptical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy - PMCPubMedDiabetic retinopathy - ocular complications of diabetes mellitus - PMC

OCT angiography (OCTA) can depict superficial and deep plexus nonperfusion and foveal avascular zone changes without dye, but flow deficits may represent capillary occlusion, true dropout, or flow below detection threshold. Use OCTA as adjunctive multimodal imaging rather than a sole determinant of severity or treatment, especially when artifact, segmentation error, or a need to demonstrate leakage limits interpretation. ScienceDirect+1ScienceDirectOptical coherence tomography angiography in diabetic retinopathy: A major review - ScienceDirectPubMedOptical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy - PMC

For center-involving DME with visual impairment, offer intravitreal anti-VEGF therapy as first-line pharmacologic treatment. Anti-VEGF therapy improves visual and anatomic outcomes and has displaced macular laser as the routine initial intervention for center-involving edema. Dosing schedules should follow the selected agent's current U.S. label and the treating retina service's protocol because the cited evidence supports treatment class selection but does not establish a universal regimen. Nature+2NatureDiabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group | EyeNatureAction on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease | EyeWolters KluwerEvidence-based review of diabetic macular edema... : Indian Journal of Ophthalmology

For non-center-involving DME, focal or grid laser remains a key treatment option. In focal clinically significant macular edema without foveal involvement, focal treatment of microaneurysms and localized leakage reduced moderate visual loss from 24% to 12%; reassess persistent leakage after 2 to 3 months and consider repeat laser. Wolters Kluwer+1Wolters KluwerEvidence-based review of diabetic macular edema... : Indian Journal of OphthalmologyPubMedDiabetic retinopathy - ocular complications of diabetes mellitus - PMC

Consider intravitreal corticosteroid therapy, including dexamethasone implant, when anti-VEGF is unsuitable or response is insufficient, particularly in pseudophakic adults. This tradeoff requires individualized selection because corticosteroid treatment is an alternative rather than routine first-line therapy in center-involving DME. Nature+2NatureDiabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group | EyeNatureAction on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease | EyeWolters KluwerEvidence-based review of diabetic macular edema... : Indian Journal of Ophthalmology

For patients who can maintain injection visits and desire fewer treatment encounters, extended-interval regimens may be appropriate. In the 96-week PHOTON trial, aflibercept 8 mg every 12 or 16 weeks after three monthly doses was noninferior to aflibercept 2 mg every 8 weeks after five monthly doses in center-involving DME, with fewer injections; faricimab also demonstrated extended durability in YOSEMITE and RHINE. ccjm+1ccjmPrint Article | Cleveland Clinic Journal of medicineccjmDiabetic retinopathy: Screening, prevention, and treatment | Cleveland Clinic Journal of medicine

Treat retinal or disc neovascularization as PDR. Panretinal photocoagulation (PRP) reduces the ischemic drive for neovascularization and is performed to prevent vitreous hemorrhage and tractional retinal detachment. PRP is particularly valuable when reliable repeated intravitreal treatment cannot be assured, because its effect does not depend on continuous injection attendance. PubMed+1PubMedDiabetic retinopathy - ocular complications of diabetes mellitus - PMCccjmPrint Article | Cleveland Clinic Journal of medicine

Intravitreal anti-VEGF therapy is a treatment option for PDR and may be combined with PRP, particularly when PDR coexists with center-involving DME. In current practice, many retina specialists use both treatments for high-risk PDR with center-involving DME. The key tradeoff is rapid pharmacologic neovascular regression versus the need for ongoing visits and the potential for tractional change in eyes with extensive fibrovascular proliferation. ccjm+1ccjmPrint Article | Cleveland Clinic Journal of medicineccjmDiabetic retinopathy: Screening, prevention, and treatment | Cleveland Clinic Journal of medicine

Assess each PDR eye for vitreous hemorrhage, fibrovascular membranes, macular traction, and retinal detachment before choosing injection-only management. In eyes with pre-existing tractional disease, laser and anti-VEGF can alter fibrovascular tissue and may rapidly worsen traction; the presence of macula-threatening traction should shift management toward surgical planning. Wolters KluwerWolters KluwerVitrectomy for diabetic retinopathy: A review of... : Taiwan Journal of Ophthalmology

Refer for pars plana vitrectomy (PPV) in PDR with nonresolving vitreous hemorrhage, tractional retinal detachment involving or threatening the macula, combined tractional-rhegmatogenous retinal detachment, or dense premacular hemorrhage. In a dense hemorrhage that prevents fundus visualization, use B-scan ultrasonography to identify detachment and prioritize urgent surgical review when the macula is threatened. Wolters Kluwer+1Wolters KluwerPerioperative anti-vascular endothelial growth... : Indian Journal of OphthalmologyPubMedOptical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy - PMC

Preoperative anti-VEGF may reduce neovascularization and intraoperative bleeding, facilitating fibrovascular membrane dissection. However, in severe tractional PDR, delayed surgery after injection can permit progressive fibrosis and tractional macular detachment. In one cited analysis, tractional macular detachment occurred in 2.7% when injection was given within 6 days of PPV versus 56% when given more than 10 days preoperatively; if anti-VEGF is used as a surgical adjunct, coordinate injection with a short, fixed path to surgery rather than an open-ended delay. NatureNaturePerioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis | Scientific Reports

Surgical goals are to release traction, reattach the retina when detached, clear nonresolving hemorrhage, and apply retinal laser to ischemic retina. Small extrafoveal tractional retinal detachments may remain stable for years and can sometimes be managed with laser rather than immediate PPV, but new macular involvement, progressive traction, or visual decline warrants surgical reassessment. Wolters KluwerWolters KluwerVitrectomy for diabetic retinopathy: A review of... : Taiwan Journal of Ophthalmology